Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)

Expert Opinion on Investigational Drugs

Volumn 17, Issue 11, 2008, Pages 1703-1715

  Anderson, Pete ^a   Kopp, Lisa ^a   Anderson, Nicholas ^b   Cornelius, Kathleen ^a   Herzog, Cynthia ^a   Hughes, Dennis ^a   Huh, Winston ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Anti IGF 1R; Antiangiogenesis; Bisphosphonates; Bone cancer; Cyclophosphamide; Denosumab; Ewing's sarcoma; Giant cell tumor; High dose methotrexate with glucarpidase; Imm Ther; Insulin growth factor receptor; Irinotecan; L MTP PE; Lung metastases; Osteosarcoma; R1507; SCH717454; Temozolomide; Topotecan

Indexed keywords

AMG 479; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CP 751871; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMC A12; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; METHOTREXATE; MK 0646; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; NVP AEW 541; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; SCH 717454; SEMAXANIB; SOMATOMEDIN C RECEPTOR; SUNITINIB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ALOPECIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BONE NECROSIS; BONE TUMOR; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DRUG POTENTIATION; DRUG PROTEIN BINDING; EWING SARCOMA; GIANT CELL TUMOR; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FAILURE; LUNG METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OSTEOSARCOMA; PROTEIN SYNTHESIS INHIBITION; REVIEW; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; OSTEOSARCOMA; SARCOMA, EWING'S;

EID: 54949093656     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.11.1703     Document Type: Review

References (76)

1. Ries L, Smith M, Gurney J, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub No 99-4649; 1999
2. Leavey PJ, Collier AB. Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 2008;8(4):617-24
3. Womer RB, West DC, Krailo MD. Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (EFST): a report from the Children's Oncology Group. J Clin Oncol 2008;26(15S):554s
4. De Angulo G, Hernandez M, Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 2007;29(1):48-52
5. Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006;24(33):5271-6
6. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006;11(5):503-19
7. Morales-Arias J, Meyers PA, Bolontrade MF, et al. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer 2007;110(7):1568-77
8. Martins AS, Ordonez JL, Garcia-Sanchez A, et al. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res 2008;68(15):6260-70
9. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50(6):1190-7
10. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004;92(1):77-91
11. Benini S, Zuntini M, Manara MC, et al. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int J Cancer 2006;119(5):1039-46
12. Strammiello R, Benini S, Manara MC, et al. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Horm Metab Res 2003;35(11-12):675-84
13. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005;65(9):3868-76
14. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007;19(4):341-6
15. Whelan J, Seddon B, Perisoglou M. Management of osteosarcoma. Curr Treat Options Oncol 2006;7(6):444-55
16. Thomas D, Chawla S, Skubitz K, et al. Denosumab treatment of giant cell tumor of bone: interim analysis of an open label phase II study. J Clin Oncol 2008;26(15S):553
17. Stenger M, Sehbai A. Denosumab: a new alternative for metastases. Commun Oncol 2008;5(6):291-4
18. Kovar H, Bernard A. CD99-positive "Ewing's sarcoma" from mouse-bone marrow-derived mesenchymal progenitor cells? Cancer Res 2006; 66(19):9786
19. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003;9(15):5442-53
20. DuBois SG, Elterman K, Grier HE. Early lymphocyte recovery in Ewing sarcoma. J Pediatr Hematol Oncol 2007;29(5):351-2
21. Worth LJ, Jia SF, An T, Kleinerman ES. ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunol Immunother 1999;48(6):312-20
22. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 2008;26(4):633-8
23. Anderson P, Hughes D, Odom LF, et al. L-MTP-PE Compassionate Access and Aerosol GM-CSF Therapy for Osteosarcoma [abstract 223; page 43]. 2008, ASPHO. Available from: http://www3.interscience.wiley-com/homepages/ 106561790/ASPHO_Abstracts_-_2008.pdf
24. Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J Clin Oncol 2001;19(15):3463-9
25. Hunold A, Weddeling N, Paulussen M. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47(6):795-800
26. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457 - a report from the Children's Oncology Group. J Clin Oncol 2006;24(1):152-9
27. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10(3):840-8
28. Wagner LM, McAllister N, Goldsby RE. et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48(2):132-9
29. Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6(10):4110-8
30. Anderson P, Aguilera D, Pearson M, Woo S. Outpatient chemotherapy plus radiotherapy in sarcomas: improving cancer control with radiosensitizing agents. Cancer Control 2008;15(1):38-46
31. Dalal S, Berry AM, Cullinane CJ, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005;11(6):2364-78
32. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
33. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7
34. Tong RT, Boucher Y, Kozin SV. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64(11):3731-6
35. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23(31):8136-9
36. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59(14):3374-8
37. Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007;25(19):2691-5
38. Shor AC, Agresta SV, D'Amato GZ, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 2008;15(1):47-54
39. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11(5):2063-73
40. Dal Monte M, Cammalleri M, Martini D, et al. Antiangiogenic role of somatostatin receptor 2 in a model of hypoxia-induced neovascularization in the retina: results from transgenic mice. Invest Ophthalmol Vis Sci 2007;48C(8):3480-9
41. Toretsky JA, Steinberg SM, Thakar M, et al. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001;92(11):2941-7
42. Beech DJ, Perer E, Helms J, et al. Insulin-like growth factor-I receptor activation blocks doxorubicin cytotoxicity in sarcoma cells. Oncol Rep 2003;10(1):181-4
43. Manara MC, Bernard G, Lollini PL, et al. CD99 acts as an oncosuppressor in osteosarcoma. Mol Biol Cell 2006;17(4):1910-21
44. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor - specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007;13(4):1322-30
45. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008;12(5):589-603
46. Zumkeller W. The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches. Sarcoma 1998;2(2):69-76
47. Scotlandi K. Targeted therapies in Ewing's sarcoma. Adv Exp Med Biol 2006;587:13-22
48. Olmos D, Okuno S, Schuetze S, et al. Safety, Pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody CP-751,871 in pateints with sarcoma. J Clin Oncol 2008;26(15S):553s
49. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK-0646, an insulin-like growthfactor-1 receptor (IGF1R) monoclonal antibody (MAb) in pateints(pts) with advanced solid tumors. J Clin Oncol 2008;26(15S):157s
50. Koshkina NV, Khanna C, Mendoza A, et al. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007;5(10):991-9
51. Balke M, Ahrens H, Streitbuerger A, et al. Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol 2008 Jun 3. [Epub ahead of print]
52. Balke M, Schremper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 2008;134(9):969-78
53. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
54. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007;119(Suppl 2):S150-62
55. Hoff AO, Toth BB, Altundag K, et al. The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23(6):826-36
56. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144(10):753-61
57. Rody WJ Jr, King GJ, Gu G. Osteoclast recruitment to sites of compression in orthodontic tooth movement. Am J Orthod Dentofacial Orthop 2001;120(5):477-89
58. Evdokiou A, Labrinidis A, Bouralexis S, et al. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003;33(2):216-28
59. Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005;104(8):1713-20
60. Anderson P. Chemotherapy for osteosarcoma with high-dose methotrexate is effective and outpatient therapy is now possible. Nat Clin Pract Oncol 2007;4(11):624-5
61. Chou AJ, Kleinerman E, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from Children's Oncology Group. J Clin Oncol 2008;26(15S):543s
62. Marina N, Bielack S, Sydes M, et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. J Clin Oncol 2007;25(18S):726s
63. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999;5(9):2316-23
64. Wylam ME, Ten R, Prakash UB, et al. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006;27(3):585-93
65. Chou AJ, Bell MD, MacKinson C, et al. Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. J Clin Oncol 2007;25(18S):532S
66. Wittgen BP, Kunst PW, van der Born K, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res 2007;13(8):2414-21
67. Chou A, Gupta R, Bell M, et al. Results of a phase IB/IIA study of SLIT (sustained release lipid inhalation targeting) cisplatin by inhalation in the treatment of patients with relapses/progressive osteosarcoa metastatic to lung. Connective Tissue Oncology Society; Seattle, WA USA; 1-3 November 2007
68. Rodriguez C, Anderson P, Cannan V, et al. Aerosol gemcitabine: in vivo antitumor activity and preclinical safety assessment in osteosarcoma bearing dogs. Connective Tissue Oncology Society (CTOS) 14th Annual Meeting; London, UK; 13-15 November 2008
69. Murakami H, Takahashi N, Sasaki T, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17(2):137-44
70. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 2007;4(12):711-21
71. Sanders JM, Ghosh S, Chan JM, et al. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 2004;47(2):375-84
72. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-31
73. Gallagher JC. Advances in bone biology and new treatments for bone loss. Maturitas 2008;60(1);65-9
74. Anderson P, Nunez R. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther 2007;7(11):1517-27
75. Mahajan A, Woo SY, Kornguth DG, et al. Multimodality treatment of osteosarcoma: radiation in a high-risk cohort. Pediatr Blood Cancer 2008;50(5):976-82
76. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124(4):619-26